Press Releases

Here you will find a range of resources including press releases and updates on approved medications that we have contributed to, and information on our social media channels

Our latest press releases and resources for media

ACT News

Albuquerque Clinical Trials awarded Full Accreditation by the Association of the Accreditation of Human Research Protection Programs, Inc (AAHRPP)

Clinic Closures

Monday January 2, 2023

New Year's Day Observed

Monday January 16, 2023

Martin Luther King, Jr. Day

Monday February 20, 2023

Presidents' Day

Monday May 29, 2023

Memorial Day

Tuesday July 4, 2023

Independence Day

Monday September 4, 2023

Labor Day

Thursday November 23, 2023

Thanksgiving Day

Friday November 24, 2023

Friday Following Thanksgiving

Friday December 22, 2023

Christmas Eve - Half Day

Monday December 25, 2023

Christmas Day

Sponsor News

Chronic Cough

Women's Health

Migraine Prevention

Cholesterol

Endometriosis

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

Merck's Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Migraine Nasal Spray

ACT Social Media

​